Drug intelligence / Profile preview

sildenafil + boceprevir

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

This is not a marketed combination product but represents a significant drug interaction. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor used for erectile dysfunction, while boceprevir is a direct-acting antiviral agent (NS3/4A protease inhibitor) formerly used to treat chronic hepatitis C. When co-administered, boceprevir significantly increases sildenafil exposure due to CYP3A4 inhibition, requiring sildenafil dose adjustment.

Targets

CYP3A4 (Cytochrome P450 3A4)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on sildenafil + boceprevir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sildenafil + boceprevir.

Explore the full profile